Cortisol and the renal handling of electrolytes: Rolein glucocorticoid-induced hypertension and bone disease

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 17, Issue 4, 2003, Pages 575-589

  Ferrari, Paolo ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

11 Hydroxysteroid dehydrogenase; Blood pressure; Bone; Calcium; Distal Kidney tubule; Glucocorticoids; Sodium

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE TYPE 2; AGENTS AFFECTING METABOLISM; ALDOSTERONE; AMINOGLUTETHIMIDE; ANABOLIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIRESORPTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CATION; CORTISONE; DIURETIC AGENT; ELECTROLYTE; FLUORIDE SODIUM; GLUCOCORTICOID; HYDROCORTISONE; KETOCONAZOLE; LOOP DIURETIC AGENT; METYRAPONE; MINERALOCORTICOID RECEPTOR; MITOTANE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SODIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ADJUVANT THERAPY; ASTHMA; BLOOD PRESSURE; BONE DISEASE; BONE METABOLISM; BONE TURNOVER; CALCIUM ABSORPTION; CALCIUM EXCRETION; CLINICAL FEATURE; CLINICAL TRIAL; CUSHING SYNDROME; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME KINETICS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCALCIURIA; HYPERTENSION; KIDNEY FUNCTION; KIDNEY TUBULE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PROPHYLAXIS; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SODIUM EXCRETION; SODIUM RESTRICTION; SODIUM RETENTION; TARGET ORGAN; VITAMIN SUPPLEMENTATION; ENZYME ACTIVITY; HORMONE ACTION; INTESTINE ABSORPTION; KIDNEY METABOLISM;

EID: 0344740887     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(03)00053-8     Document Type: Review

References (94)

1. Tauchmanova L, Rossi R, Biondi B et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. Journal of Clinical Endocrinology and Metabolism 2002; 87: 4872-4878.
2. Canalis E. Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis. Journal of Clinical Endocrinology and Metabolism 1996; 81: 3441-3447.
3. Ferrari P & Krozowski Z. Role of the 11β-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney International 2000; 57: 1374-1381.
4. Funder JW, Pearce PT, Smith R et al. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583-585.
5. Ferrari P, Obeyesekere VR, Li K et al. The 11β-hydroxysteroid dehydrogenase type II enzyme: Biochemical consequences of the congenital R337C mutation. Steroids 1996; 61: 197-200.
6. Ferrari P, Smith RE, Funder JW et al. Substrate and inhibitor specificity of the cloned human 11β-hydroxysteroid dehydrogenase type 2 isoform. American Journal of Physiology 1996; 270: E900-E904.
7. Canalis E & Delany AM. Mechanisms of glucocorticoid action in bone. Annals of the New York Academy of Sciences 2002; 966: 73-81.
8. Resnick LM & Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. American Journal of Medicine 1985; 78: 385-390.
9. Ferrari P, Bianchetti MG, Sansonnens A et al. Modulation of renal calcium handling by 11β-hydroxysteroid dehydrogenase type 2. Journal of the American Society of Nephrology 2002; 13: 2540-2546.
10. Ferrari P & Bonny O. Forms of mineralocorticoid hypertension. Vitamins and Hormones 2003; 66: 113-156.
11. Stewart PM. Mineralocorticoid hypertension. Lancet 1999; 353: 1341-1347.
12. Ferrari P, Bianchetti M & Frey FJ. Juvenile hypertension, the role of genetically altered steroid metabolism. Hormone Research 2001; 55: 213-223.
13. Ferrari P. Genetics of the mineralocorticoid system in primary hypertension. Current Hypertension Reports 2002; 4: 18-24.
14. Arriza JL, Weinberger C, Cerelli G et al. Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science 1987; 237: 268-275.
15. Agarwal AK, Monder C, Eckstein B et al. Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. Journal of Biological Chemistry 1989; 264: 18939-18943.
16. Albiston AL, Smith RE, Obeyesekere VR et al. Cloning of the 11βHSD type II enzyme from human kidney. Endocrine Research 1995; 21: 399-409.
17. Tannin GM, Agarwal AK, Monder C et al. The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. Journal of Biological Chemistry 1991; 266: 16653-16658.
18. Albiston AL, Obeyesekere VR, Smith RE et al. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Molecular Cell Endocrinology 1994; 105: RII-R17.
19. Agarwal AK, Mune T, Monder C et al. NAD(+)-dependent isoform of 11β-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. Journal of Biological Chemistry 1994; 269: 25959-25962.
20. Krozowski Z, MaGuire JA, Stein-Oakley AN et al. Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. Journal of Clinical Endocrinology and Metabolism 1995; 80: 2203-2209.
21. New MI, Levine LS, Biglieri EG et al. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. Journal of Clinical Endocrinology and Metabolism 1977; 44: 924-933.
22. Ulick S, Levine LS, Gunczler P et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. Journal of Clinical Endocrinology and Metabolism 1979; 49: 757-764.
23. Wilson RC, Krozowski ZS, Li K et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. Journal of Clinical Endocrinology and Metabolism 1995; 80: 2263-2266.
24. Mune T, Rogerson FM, Nikkila H et al. Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nature Genetics 1995; 10: 394-399.
25. Obeyesekere VR, Ferrari P, Andrews RK et al. The R337C mutation generates a high Km 11β-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. Journal of Clinical Endocrinology and Metabolism 1995; 80: 3381-3383.
26. Wilson RC, Harbison MD, Krozowski ZS et al. Several homozygous mutations in the gene for 11β-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. Journal of Clinical Endocrinology and Metabolism 1995; 80: 3145-3150.
27. Ferrari P, Obeyesekere VR, Li K et al. Point mutations abolish 11β-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Molecular Cell Endocrinology 1996; 119: 21-24.
28. Wilson RC, Dave-Sharma S, Wei JQ et al. A genetic defect resulting in mild low-renin hypertension. Proceedings of the National Academy of Sciences of the USA 1998; 95: 10200-10205.
29. Stewart PM, Wallace AM, Valentino R et al. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; (ii): 821-824.
30. Ferrari P, Sansonnens A, Dick B et al. In vivo 11βHSD-2 activity: Variability, salt-sensitivity, and effect of licorice. Hypertension 2001; 38: 1330-1336.
31. Vidal Trecan G, Laudat MH, Thomopoulos P et al. Urinary free corticoids: An evaluation of their usefulness in the diagnosis of Cushing's syndrome. Acta Endocrinologica (Copenhagen) 1983; 103: 110-115.
32. Mengden T, Hubmann P, Muller J et al. Urinary free cortisol versus 17-hydroxycorticosteroids: A comparative study of their diagnostic value in Cushing's syndrome. Clinical Investigation 1992; 70: 545-548.
33. Ulick S, Wang JZ, Blumenfeld JD et al. Cortisol inactivation overload: A mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. Journal of Clinical Endocrinology and Metabolism 1992; 74: 963-967.
34. Stewart PM, Walker BR, Holder G et al. 11β-hydroxysteroid dehydrogenase activity in Cushing's syndrome: Explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. Journal of Clinical Endocrinology and Metabolism 1995; 80: 3617-3620.
35. Palermo M, Shackleton CH, Mantero F et al. Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clinical Endocrinology 1996; 45: 605-611.
36. Montrella-Wabill M, Clore JN, Schoolwerth AC et al. Evidence that high dose cortisol-induced Na + retention in man is not mediated by the mineralocorticoid receptor. Journal of Clinical Endocrinology and Metabolism 1991; 72: 1060-1066.
37. Williamson PM, Kelly JJ & Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. Journal of Hypertension 1996; 14(Supplement): S37-S41.
38. Fanestil DD. Mode of spirolactone action: Competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors. Biochemical Pharmacology 1968; 17: 2240-2242.
39. Gomez-Sanchez EP & Gomez-Zanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. American Journal of Physiology 1992; 263: EII25-EII30.
40. Funder JW. Mineralocorticoid receptors in the central nervous system. Journal of Steroid Biochemistry and Molecular Biology 1996; 56: 179-183.
41. Palermo M, Cossu M & Shackleton CH. Cure of apparent mineralocorticoid excess by kidney transplantation. New England Journal of Medicine 1998; 339: 1787-1788.
42. Mantero F, Armanini D & Boscaro M. Plasma renin activity and urinary aldosterone in Cushing's syndrome. Hormone and Metabolic Research 1978; 10: 65-71.
43. Takeda Y, Miyamori I, Yoneda T et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. Journal of Clinical Endocrinology and Metabolism 1996; 81: 2797-2800.
44. Honda M, Nowaczynski W, Guthrie Jr GP et al. Response of several adrenal steroids to ACTH stimulation in essential hypertension. Journal of Clinical Endocrinology and Metabolism 1977; 44: 264-272.
45. Hautanena A, Lankinen L, Kupari M et al. Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males. Journal of Internal Medicine 1998; 244: 11-18.
46. Kelly JJ, Mangos G, Williamson PM et al. Cortisol and hypertension. Clinical and Experimental Pharmacology and Physiology 1998; 25(supplement): S51-S56.
47. Kelly JJ, Williamson P, Martin A et al. Effects of oral L-arginine on plasma nitrate and blood pressure in cortisol-treated humans. Journal of Hypertension 2001; 19: 263-268.
48. Van Staa TP, Leufkens HG, Abenhaim L et al. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 1383-1389.
49. Silvestrini G, Mocetti P, Ballanti P et al. Cytochemical demonstration of the glucocorticoid receptor in skeletal cells of the rat. Endocrine Research 1999;25:117-128.
50. Weinstein RS, Jilka RL, Parfitt AM et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. Journal of Clinical Investigation 1998; 102: 274-282.
51. Chen J, Thomas HF & Sodek J. Regulation of bone sialoprotein and osteopontin mRNA expression by dexamethasone and 1,25-dihydroxyvitamin D3 in rat bone organ cultures. Connective Tissue Research 1996; 34: 41-51.
52. Diamond T, Levy S, Day P et al. Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: Effects of glucocorticoid therapy and disease activity. British Journal of Haematology 1997; 97: 641-648.
53. Gennari C. Differential effect of glucocorticoids on calcium absorption and bone mass. British Journal of Rheumatology 1993; 32(supplement 2): 11-14.
54. Lukert BP & Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Annals of Internal Medicine 1990; 112: 352-364.
55. Reid IR. Glucocorticoid osteoporosis - Mechanisms and management. European Journal of Endocrinology 1997; 137: 209-217.
56. Rossi E, Sani C, Perazzoli F et al. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. American Journal of Hypertension 1995; 8: 884-893.
57. Cosman F, Nieves J, Herbert J et al. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. Journal of Bone and Minereral Research 1994; 9: 1097-1105.
58. Martell-Claros N, Fernandez-Pinilla C, De La Quadra F et al. Calcium intake, calcium excretion and blood pressure in adolescents in the upper decile of the distribution: The Torrejon study. Journal of Hypertension 1989; 7(supplement): S256-S257.
59. Biner HL, Arpin-Bott MP, Loffing J et al. Human cortical distal nephron: Distribution of electrolyte and water transport pathways. Journal of the American Society of Nephrology 2002; 13: 836-847.
60. Velazquez H, Naray-Fejes-Toth A, Silva T et al. Rabbit distal convoluted tubule coexpresses NaCl cotransporter and IIβ-hydroxysteroid dehydrogenase II mRNA. Kidney International 1998; 54: 464-472.
61. Bostanjoglo M, Reeves WB, Reilly RF et al. IIβ-hydroxysteroid dehydrogenase, mineralocorticoid receptor, and thiazide-sensitive Na-Cl cotransporter expression by distal tubules. Journal of the American Society of Nephrology 1998; 9: 1347-1358.
62. Carballeira A, Fishman LM & Jacobi JD. Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: Correlation of in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism 1976; 42: 687-695.
63. Verhelst JA, Trainer PJ, Howlett TA et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clinical Endocrinology (Oxford) 1991; 35: 169-178.
64. Pont A, Goldman ES, Sugar AM et al. Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. Archives of Internal Medicine 1985; 145: 1429-1431.
65. Engelhardt D, Dorr G, Jaspers C et al. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal II beta-hydroxylase. Klin Wochenschr 1985; 63: 607-612.
66. Sonino N, Boscaro M, Paoletta A et al. Ketoconazole treatment in Cushing's syndrome: Experience in 34 patients. Clinical Endocrinology (Oxford) 1991; 35: 347-352.
67. Tabarin A, Navarranne A, Guerin J et al. Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome. Clinical Endocrinology (Oxford) 1991; 34: 63-69.
68. Misbin RI, Canary J & Willard D. Aminoglutethimide in the treatment of Cushing's syndrome. Journal of Clinical Pharmacology 1976; 16: 645-651.
69. Luton JP, Cerdas S, Billaud L et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine 1990; 322: 1195-1201.
70. Haak HR, Caekebeke-Peerlinck KM, Van Seters AP et al. Prolonged bleeding time due to mitotane therapy. European Journal of Cancer 1991; 27: 638-641.
71. Krakoff LR & Elijovich F. Cushing's syndrome and exogenous glucocorticoid hypertension. Clinical Endocrinology and Metabolism 1981; 10: 479-488.
72. Fallo F, Paoletta A, Tona F et al. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. Journal of Internal Medicine 1993; 234: 595-598.
73. Stimpel M, Ivens K, Volkmann HP et al. Therapeutic value of calcium antagonists in autonomous hyperaldosteronism. Klin Wochenschr 1989; 67: 248-252.
74. Veglio F, Pinna G, Bisbocci D et al. Efficacy of nicardipine slow release (SR) on hypertension, potassium balance and plasma aldosterone in idiopathic aldosteronism. Journal of Human Hypertension 1990; 4: 579-582.
75. Stimpel M, Ivens K, Wambach G et al. Are calcium antagonists helpful in the management of primary aldosteronism? Journal of Cardiovascular Pharmacology 1988; 12(supplement 6): S131-S134.
76. Reid DM, Nicoll JJ, Smith MA et al. Corticosteroids and bone mass in asthma: Comparisons with rheumatoid arthritis and polymyalgia rheumatica. British Medical Journal 1986; 293: 1463-1466.
77. Wang WQ, Ip MS, Tsang KW et al. Antiresorptive therapy in asthmatic patients receiving high-dose inhaled steroids: A prospective study for 18 months. Journal of Allergy and Clinical Immunology 1998; 101: 445-450.
78. Adachi JD, Bensen WG, Bianchi F et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3-year follow-up. Journal of Rheumatology 1996; 23: 995-1000.
79. Buckley LM, Leib ES, Cartularo KS et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1996; 125: 961-968.
80. Adams JS, Wahl TO & Lukert BP. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981; 30: 217-221.
81. LaCroix AZ, Ott SM, Ichikawa L et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 2000; 133: 516-526.
82. Stier Jr. CT & Itskovitz HD. Renal calcium metabolism and diuretics. Annual Review of Pharmacology Toxicology 1986; 26: 101-116.
83. Reusz GS, Dobos M, Vasarhelyi B et al. Sodium transport and bone mineral density in hypercalciuria with thiazide treatment. Pediatric Nephrology 1998; 12: 30-34.
84. Reid IR, Ames RW, Orr-Walker BJ et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: A randomized controlled trial. American Journal of Medicine 2000; 109: 362-370.
85. LaCroix AZ, Wienpahl J, White LR et al. Thiazide diuretic agents and the incidence of hip fracture. New England Journal of Medicine 1990; 322: 286-290.
86. Felson DT, Sloutskis D, Anderson JJ et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA 1991; 265: 370-373.
87. Cauley JA, Cummings SR, Seeley DG et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The study of Osteoporotic Fractures Research Group. Annals of Internal Medicine 1993; 118: 666-673.
88. Jones G, Nguyen T, Sambrook PN et al. Thiazide diuretics and fractures: Can meta-analysis help? Journal of Bone and Minereral Research 1995; 10: 106-111.
89. Yamada H. Long-term effect of I alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis. Nippon Naibunpi Gakkai Zasshi 1989; 65: 603-614.
90. Hall GM, Spector TD & Delmas PD. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. Arthritis and Rheumatism 1995; 38: 902-906.
91. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine 1997; 337: 1641-1647.
92. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999; 282: 637-645.
93. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. New England Journal of Medicine 1998; 339: 292-299.
94. Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and Rheumatism 1999; 42: 2309-2318.